

Applicants : Rina Aharoni et al.
U.S. Serial No.: 09/768,872
August 22, 2003 Amendment under 37 C.F.R. § 1.116
Page 9

conceive of pharmaceutical compositions containing such terpolymers as recited in now-canceled claims 1-4.

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

To ensure compliance with their duty of disclosure under 37 C.F.R. §1.56, applicants wish to draw the Examiner's attention to the fact that their substitute specification filed January 23, 2001, in addition to deleting certain disclosure, deleted a cross-reference to U.S. Provisional Application No. 60/123,675, filed March 9, 1999, which cross-reference was present in the originally filed specification. On August 1, 2001, applicants filed a Declaration and Power of Attorney claiming the benefit of U.S. Provisional Application Nos. 60/093,859, filed July 23, 1998, 60/101,825, filed September 25, 1998, 60/102,960, filed October 2, 1998, 60/106,350, filed October 30, 1998, and 60/108,184, filed November 12, 1998, but not of U.S. Provisional Application No. 60/123,675. A copy of U.S. Provisional Application No. 60/123,675 is attached hereto as **Exhibit 1** and a PTO Form-1449 listing U.S. Provisional Application No. 60/123,675 is attached hereto as **Exhibit A**.

The claim to the benefit of U.S. Provisional Application No. 60/123,675 has been made in U.S. Serial No. 09/359,099, filed July 22, 1999, which was disclosed in applicants' June 26, 2002 Information Disclosure Statement in connection with the subject application. U.S. Serial No. 09/359,099 lists a different inventive entity², is assigned to a different entity³ and is prosecuted by a different attorney from the subject application. Applicants are aware of U.S. Serial No. 09/359,099 by virtue of

² Jack L. Strominger and Masha Fridkis-Hareli

³ The President and Fellows of Harvard College

Applicants : Rina Aharoni et al.
U.S. Serial No.: 09/768,872
August 22, 2003 Amendment under 37 C.F.R. § 1.116
Page 10

an agreement between the licensee of the subject application and the assignee of U.S. Serial No. 09/359,099.

Allowable Subject Matter


The Examiner stated that claims 16-20 and 32-39 contain allowable subject material.


Accordingly, applicants maintain that the application is now in condition for allowance and earnestly solicit a notice of allowance of claims 16-20, 32-39 and 157-165.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the enclosed \$110.00 for the one-month extension of time, is deemed necessary in connection with the filing of this Amendment. However, if any additional fee is deemed necessary, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	
	8/22/03
John P. White Reg. No. 28,678	Date


John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400



Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Atty. Docket No. 60772-PCT-US/ JPW/ GJG/CSN	Serial No. 09/768,872
	Applicants: Rina Aharoni et al.	
	Filing Date January 23, 2001	Group Art Unit 1644

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number								Date	Name	Class	Subclass	Filing Date if Appropriate
	US	60	1	2	3	6	7	5		03/09/99	Strominger et al.			

FOREIGN PATENT DOCUMENTS

		Document Number								Date	Country	Class	Subclass	Translation	
														Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER**DATE CONSIDERED**

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.